Overall, 945 cases and controls were included in this study. We identified 100 breast cancer, 64 melanoma, and 25 lymphoma patients with CNS metastasis or infiltration (N = 189 cases). With 4 controls per case, we also identified 400 breast cancer, 256 melanoma, and 100 NHL patients without CNS metastasis or infiltration (N = 756 controls). Of these controls, 200 breast cancer patients, 128 melanoma patients and 50 NHL patients had another diagnosed metastasis but not CNS involvement [N = 378; controls (other metastasis)] including metastasis to the bone (n = 204), lung and pleura (n = 170), liver (n = 104), skin and subcutaneous tissue (n = 35), bone marrow (n = 13), and several other less common sites of metastasis (n = 90) including metastasis to the spleen, adrenal glands, breast, small intestine, pancreas, and testes. The other 200 breast cancer patients, 128 melanoma patients and 50 NHL patients had no metastasis [N = 378; controls (no metastasis)].
Antidepressant use
'Any antidepressant use' was the primary exposure and was defined as the use of any antidepressant irrespective of class (SSRI, SNRI, atypical, tricyclics and tetracyclics, and/or MAOIs) as recorded in patients' medical records. If a subject used ≥1 type of antidepressant, he/she was grouped as 'yes' for taking an antidepressant. Otherwise, antidepressant use was coded as 'no'. 'Any SSRI use' was defined as use of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and/or vilazodone or any of their generic forms [1, 4, 29, 30] . 'Exclusive SSRI use' was defined as those subjects who have only taken SSRIs and no other class, as recorded in their medical record. All antidepressant use categories were defined as 'yes' or 'no' if they were documented any time 1 year to 1 month before CNS metastasis or infiltration was diagnosed. The 1 month period prior to CNS involvement was excluded to account for the lag time between actual metastasis and diagnosis. Of note, this 1 year period could begin before or after the patient's initial cancer diagnosis. Although antidepressant use during this time period could be determined, the dose, starting date, and, consequently, duration of the antidepressants were mostly missing due the nature of the medical records.
Statistical analysis
All analyses determined the relative odds of CNS involvement associated with antidepressant use. Differences existed in the definition of our exposure ('any antidepressant use', 'any SSRI use', 'exclusive SSRI use'), which necessitated several models evaluating confounding due to different exposures, control groups, and cancers (all cancers, breast cancer alone, melanoma alone). The primary analysis was conducted using cases and controls (all controls regardless antidepressant use in the cancer population ranged from 10 to 34 % [17, [20] [21] [22] [23] [24] [25] [26] [27] [28] and 19 to 31 % for SSRI users [22, 26] . However, the side effects of these medications are not fully known. Since cancer patients are frequently prescribed antidepressants, the potential impact of these medications have on the dissemination of this disease to the CNS needs to be understood. Using a case-control study, we hypothesized that increased antidepressant use after cancer diagnosis would be associated with increased odds of CNS metastasis or infiltration in breast cancer, non-Hodgkin lymphoma (NHL), and melanoma patients.
Methods

Study design and study population
Subjects were selected from patients seen at the University of Rochester Medical Center (URMC) from January 1, 2005 to September 30, 2013. Cases were adults (over the age of 18 years) with inpatient admissions or outpatient visits with an ICD-9 code of breast cancer, NHL, or melanoma (174.0-174.9, 200.0-204.1, and 172.0-172.9, respectively), and a CNS metastasis or infiltration diagnosis (198.3) in their medical record. Males and females were included for cases with a diagnosis of NHL or melanoma, but breast cancer was limited to females. Additional exclusion criteria for the cases included a diagnosis of lung cancer, multiple sclerosis or human immunodeficiency virus (HIV), a stroke 6 months prior to CNS metastasis or infiltration, a traumatic brain injury, or any documented drug abuse as these diagnoses have been known to affect the blood-brain barrier and our proposed mechanism. Patients with a previous diagnosis of lung cancer were excluded since the CNS metastasis was likely due to the lung cancer and patients were actively being treated for their lung cancer. Other previous cancer diagnoses were included as long as the previous cancer was not actively treated in the year prior to the CNS metastasis, and the medical charts recorded that the CNS metastasis was related to breast cancer, melanoma, or NHL.
While cases had a CNS metastasis or infiltration diagnosis, controls did not have this diagnosis. All other inclusion and exclusion criteria for controls were similar to the cases. Two secondary sets of controls were defined: those cancer patients with metastasis other than CNS metastasis or infiltration [controls (other metastasis)] and those cancer patients with no metastasis [controls (no metastasis)]. Controls (other metastasis) were comprised of patients with stage IV cancer in melanoma and breast cancer, similar to our cases. For NHL, "other metastasis" was defined as other extranodal sites, including bone marrow. Patients with no metastasis or no extranodal sites were excluded from this control group; these patients are labeled as controls (no metastasis).
other metastasis = 46.0 %), while the cases had more multiple sites of metastasis (cases = 67.9 %, controls other metastasis = 54.0 %) (data not shown). Of those cancer patients in controls (no metastasis), 24.3 % developed metastasis after study inclusion (data not shown).
Antidepressant use, by control group compared to the cases (all cancers types together), is shown in Table 2 . SSRI use was the most commonly used antidepressant among cases and controls (cases = 16.9 %, controls = 17.3 %). Antidepressant use and SSRI use were similar between cases and controls (antidepressant use: cases = 28.6 %, controls = 27.5 %; SSRI use: cases = 16.9 %, controls = 17.3 %) ( Table 2 ).
Multivariable analyses
Adjusted odds ratios (OR) are presented separately for each control group (controls, controls other metastasis, and controls no metastasis) in Table 3 . Within each control group, we present the results for all cancers and then separately for the breast cancer and melanoma subsets. We did not find any statistically significant increased odds of CNS metastases or infiltration associated with antidepressant use, when using any of the three control groups, any grouping of antidepressants, or when examining breast or melanoma cancer alone. Cancer patients being diagnosed with CNS metastasis or infiltration did not have greater odds of having used antidepressants compared to those cancer patients who develop CNS metastasis (any antidepressants: OR = 1.16, 95 % CI = 0.78, 1.73; any SSRIs: OR = 1.21, 95 % CI = 0.74, 1.97; exclusive SSRIs: OR = 1.36, 95 % CI = 0.80, 2.31). However, this study, with its sample size of 189 cases and 756 controls, did not have sufficient statistical power to find an effect size of less than 1.61.
No statistically significant results were found in any of the subset analyses. However, in the breast cancer subset of controls (other metastases), all odds ratios of CNS metastasis associated with antidepressant use were consistent in direction, and magnitude increased from 'any antidepressant use' (OR = 1.11) to 'any SSRI use' (OR = 1.73). Similarly, non-significant results were seen in the melanoma subset for 'any antidepressant use' (OR = 1.69, 95 % CI = 0.77, 3.72), 'any SSRIs' (OR = 1.24, 95 % CI = 0.43, 3.55), and 'exclusive SSRIs' (OR = 1.56, 95 % CI = 0. 46, 5.35) .
Discussion
This is the first study to assess the association between antidepressant use and CNS metastasis or infiltration among breast cancer, melanoma, and NHL patients. Overall, we found no association between antidepressant use and CNS metastasis or infiltration with the possible exception of an of metastasis). Secondary analyses were conducted using cases and the secondary control groups: controls (other metastasis) and controls (no metastasis). All statistical analyses were performed using SAS version 9.3 (Cary, NC).
In order to build our statistical models, the following variables were considered: age, gender (male, female), race (white, nonwhite), stage (I, II, III, IV), radiation (yes, no), chemotherapy (yes, no), immunotherapy (yes, no), surgery (yes, no), and type of metastasis (yes, no for each: bone metastasis, bone marrow metastasis, lung/pleural metastasis, liver metastasis, skin/subcutaneous metastasis, and other sites of metastasis), based on previous studies [31] [32] [33] [34] [35] [36] [37] . All potential covariates were recorded at the time of diagnosis, with the exception of treatment, which was documented at any point in the patient's documented cancer history until their CNS metastasis or infiltration. Treatment after or for their CNS metastasis or infiltration was not included. For those continuous and categorical variables, the best functional form was evaluated and analyzed. A logistic regression model was built using a manual backward selection method, including variables that were associated with CNS metastasis or infiltration at p < 0.20. Subset analyses were planned a priori, creating separate analyses, conducted in the same manner described above, for breast cancer and melanoma, separately. Subset analyses could not be conducted on the NHL subset due to the small sample size (cases n = 25, controls n = 100). For the subset analysis in breast cancer, two categorical variables were added: type of breast cancer (ductal, lobule, and other) and molecular subtype (HER2, triple negative, luminal A, and luminal B). In the melanoma subset analysis a categorical location variable was added (head and neck, trunk, extremity, other, and unknown).
Results
Population characteristics
Population characteristics, by case and control status, are shown in Table 1 . Cases were mostly stage II, III, and IV cancers at diagnosis (stage 0 and I = 10.0 %, stage II = 31.2 %, stage III = 34.7 %, and stage IV = 24.1 %), while controls were more often stage 0 and 1 and fewer stage IV cancers (stage 0 and I = 18.6 %, stage II = 32.6 %, stage III = 35.4 %, and stage IV = 13.5 %). CNS metastasis cases received more therapy than controls, with a higher percent of patients receiving chemotherapy (cases = 81.0 %, controls = 58.3 %), surgery (cases = 79.9 %, controls = 77.5 %), radiation (cases = 58.2 %, controls = 45.8 %), and immunotherapy (cases = 44.4 %, controls = 34.8 %) (Table 1) . Controls (other metastasis) developed single sites of metastasis more frequently than the cases (cases = 32.1 %, controls relationship [7, 13, [38] [39] [40] [41] . One of the mechanisms for this increase in brain metastasis was an inflammatory process. The inflammatory cytokines TNF-α and IL-1β were upregulated in the brains of those mice that received fluoxetine by 4.96-fold and 3.76-fold, respectively (p < 0.05) [7] . Additionally, IL-1β and TNF-α increased BBB permeability [9, 10] , and absorption of Evans Blue, a dye used as marker for determining BBB permeability, was 54 % higher in mice treated with fluoxetine compared to controls (p < 0.01) [7] . increased risk of CNS metastases (albeit statistically imprecise and not statistically significant), associated with 'any SSRI use' among breast cancer patients. Our results do not support the previous finding of Shapovalov et al. [7] who found a 52 % increase in number of brain metastases in mice associated with fluoxetine.
Although we did not find a statistically significant association between antidepressant use and CNS metastasis, several mechanistic studies have supported this potential There are several strengths to this study, including that antidepressant use in our cancer study population (27.7 %) was similar to antidepressant use documented in previous studies (10-34 %) [17, [21] [22] [23] [24] [25] [26] . Additionally, the characteristics of our CNS metastasis cases in our study were similar to previous studies [31, 32, 35, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] , suggesting that the reason we did not find a clear strong association between CNS metastases or infiltration and antidepressant use in our study was not due to differences in our cases. Second, we investigated SSRIs in addition to a combined 'any antidepressants' category. Lastly, this study was designed as a case-control. Although the case-control study design is retrospective in nature, we eliminated some of the problems inherent to retrospective studies. For example, our study eliminated some recall bias because the data on antidepressant use was recorded previously. We sampled cases and controls from the same population ensuring the controls represented the source population from which the cases arose [1], thereby reducing the potential for selection bias.
There were several limitations of the study that should be considered when making inference. First, we assumed that CNS metastasis or infiltration occurs similarly and via the same pathway in all cancer types studied; however, we have no knowledge if the inflammatory process acts differently across cancers. If it acts differently, we could be missing the true effect by combining these three cancers. Second, we grouped all three cancers into one large group to maximize statistical power. We grouped lymphoma, a hematological cancer, with solid tumors: melanoma and breast cancer. Staging and treatment are different in these cancers. We conducted a subset analysis to determine if the effect appears in each cancer separately and found the direction of the breast cancer and melanoma subsets were similar using controls (other metastasis) ('any antidepressant use': breast cancer-OR = 1.11, melanoma-OR = 1.69; 'any SSRI use': breast cancer-OR = 1.73, melanoma-OR = 1.24; 'exclusive SSRI use': breast cancer-OR = 1.67, melanoma-OR = 1.56), but using controls (No metastasis), the direction of the odds ratios of the cancer subsets were different ('any antidepressant use': breast cancer-OR = 1.33, This observation of upregulated TNF-α and IL-1β along with the findings from Tynan et al. [13] suggests fluoxetine may increase neuroinflammation and increase brain metastases. These associations were not observed in all studies [14, 15] , although these differences may result from differences in in vitro and in vivo settings and lack of baseline measurements. Additionally, glia may contribute to this inflammatory process by producing cytokines including IL-1β and TNF-α [7] . Glial cells may also affect metastatic growth within the brain [39, 41] and be used by tumor cells to support its progression and invasion [38, 40] . Inflammation may also compound the potential effect fluoxetine may have on the metastatic process. These impacted processes include improved arrest of tumor cells in the brain vasculature and enhanced extravasation [8] . Shapovalov et al. [7] suggest inflammation may increase the survival of these tumor cells once they arrest in the brain vasculature. We found a non-significant difference between the relative odds of CNS metastasis or infiltration associated with antidepressant use when using controls (other metastasis) and controls (no metastasis). We suggest this difference resulted from the control groups being at different points in the metastatic process. This improvement in the steps of the metastatic process from an antidepressant would only increase CNS metastasis or infiltration in those cancers that have already begun the metastatic process, such as those of controls (other metastasis). Whereas, those subjects of controls (no metastasis) have not begun the metastatic process and would not benefit from an improvement in any step other than the initial cellular division and growth within the primary tumor.
Breast cancer patients diagnosed with CNS metastasis were more likely to report taking 'any SSRIs' in comparison to those who do not have CNS metastasis, when controlling Controls (other mets): All cancers controlled for stage, chemotherapy, surgery, and bone metastasis. The breast cancer subset was controlled for race, chemotherapy, bone metastasis, and molecular subtype. The melanoma subset was controlled for stage, melanoma location, chemotherapy, and skin metastasis or second melanomas b Controls (no mets): All cancers controlled for stage, age, chemotherapy, radiation, and immunotherapy. The breast cancer subset was controlled for age, chemotherapy, radiation, and molecular subtype. The melanoma subset was controlled for stage, melanoma location, chemotherapy, surgery, and radiation c Total controls: All Cancers controlled for stage, age, chemotherapy, radiation, bone marrow metastasis, lung and pleural metastasis, and other sites of metastasis. The breast cancer subset was controlled for age, chemotherapy, radiation, bone metastasis, bone marrow metastasis, lung and pleural metastasis, and molecular subtype. The melanoma subset was controlled for chemotherapy, lung and pleural metastasis, and other sites of metastasis this would only occur in those with CNS metastasis) and an overestimation of our effect estimates. Overall, we found no association between antidepressant use and CNS metastasis or infiltration. We suggest that future studies with larger sample sizes further investigate SSRI use in breast cancer patients. To reduce exposure measurement error and improve the validity of associations, such studies should use prospectively-collected pharmacy data and identify dose and duration of antidepressant use.
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Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent was not required. . However, these analyses were underpowered. Further, this combination of different cancer types could have induced residual confounding through the misspecification of some of these variables. Third, since we could only define antidepressant use via the medical record, we could only categorize a subject as using antidepressants or not using antidepressants and could not collect data on dose or duration of use. Since antidepressants act differently at different dose levels [13] , the use of only a binary variable to characterize antidepressant use (Yes versus No) may introduce non-differential exposure misclassification, a bias towards the null, and underestimates of the relative odds of CNS metastasis or infiltration associated with antidepressant use. Fourth, we were unable to capture antidepressant use prior to their initial cancer diagnosis as the majority of the patients' charts began at this time. Fifth, antidepressant use may have not been documented in the patients' charts, particularly if the antidepressant was prescribed outside of oncology and not recorded. This exposure misclassification, which is not likely different for those with and without CNS metastasis or infiltration, may have biased our results towards the null and underestimated the true odds ratio. Additionally, uncertainty exists with regards to the latency of CNS metastasis or infiltration. A lag time likely exists between CNS metastasis or infiltration onset and diagnosis. However, the exact length of time is unknown and may differ by type of cancer and patient. Although we proposed that a month was long enough to account for this latency, the actual time may be longer, which could result in CNS metastases inducing depression and preceding antidepressant use. If our assumption was incorrect, we could have created differential exposure misclassification, which would result in a bias away from the null and an overestimation of the relative odds of CNS metastasis or infiltration. Furthermore, no direction of causation can be assumed. The possibility exists that patients who end up developing CNS metastasis or infiltration, in general, have a worse prognosis (e.g. more sites of peripheral metastasis) and therefore are more likely to be depressed as a consequence of their diagnosis and as a result take more antidepressants. Last, the exact time in which antidepressant use affects CNS metastasis or infiltration is unknown, in part due to uncertainty with regards to the metastatic process. The exposure must occur once the metastatic cancer cells are in the circulatory system, but this exact time period is difficult to predict. If we were incorrect in our assumption and we included those patients whose only antidepressant use was actually after CNS metastasis or infiltration, this may have resulted in differential exposure misclassification (i.e. those subjects who were categorized as exposed were really unexposed and
